Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAT | P00750 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.31 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1069091 | 0.90 | PLAT (0.35) | PLATGPR119CYP3A4CYP2C19GABRG2 | |
| SCHEMBL386402 | 0.89 | PLAT (0.36) | PLATGPR119CYP3A4CYP2C19GABRG2 | |
| SCHEMBL389604 | 0.88 | GPR119 (0.39) | PLATGPR119CYP3A4CYP2C19CNR2 | |
| SCHEMBL12904231 | 0.85 | PLAT (0.35) | PLATGPR119CYP3A4CYP2C19GABRG2 | |
| SCHEMBL386758 | 0.84 | GPR119 (0.40) | PLATGPR119CYP3A4CYP2C19CNR2 | |
| SCHEMBL390170 | 0.84 | GPR119 (0.45) | PLATGPR119CYP3A4CYP2C19 | |
| SCHEMBL12835430 | 0.83 | PLAT (0.37) | PLATGPR119CYP3A4CYP2C19GABRG2 | |
| SCHEMBL12914997 | 0.82 | PLAT (0.37) | PLATGPR119CYP3A4CYP2C19GABRG2 | |
| SCHEMBL386155 | 0.82 | TACR2 (0.39) | — | |
| SCHEMBL388247 | 0.80 | GPR119 (0.37) | PLATGPR119CYP3A4CYP2C19GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1758565-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL | Arena Pharmaceuticals, Inc. (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2006076231-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL | ARENA PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | WO | disclosed |